Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy, and future strategies

Reviews of Infectious Diseases

Volumn 10, Issue 3, 1988, Pages 560-586

  Herman, Jonathan D ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; ANTIPROTOZOAL AGENT; LIPID; POLYAMINE; PURINE DERIVATIVE;

ANIMAL; CHEMISTRY; ENERGY METABOLISM; HUMAN; LEISHMANIA; LEISHMANIASIS; METABOLISM; REVIEW; VISCERAL LEISHMANIASIS;

ANIMAL; ANTIMONY; ANTIPROTOZOAL AGENTS; CHEMISTRY; ENERGY METABOLISM; HUMAN; LEISHMANIA; LEISHMANIASIS; LEISHMANIASIS, VISCERAL; LIPIDS; POLYAMINES; PURINES;

EID: 0024004690     PISSN: 01620886     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/10.3.560     Document Type: Article

References (187)

1. Sukkar F. Leishmaniasis in the Middle East. In: Chang K-P, Bray RS, eds. Human parasitic diseases. Vol 1. Amsterdam: Elsevier, 1985:393-413
2. Goldman L. Pre-Colombian leishmaniasis [letter]. Arch Der-matol 1983;119:540
3. Herrer A, Christensen HA. Implication of Phlebotomus sand flies as vectors of bartonellosis and leishmaniasis as early as 1764. Science 1975;190:154-5
4. Hoare CA. Early discoveries regarding the parasite of oriental sore. Trans R Soc Trop Med Hyg 1938;32:67-92
5. Leishman WB. On the possibility of the occurrence of trypanosomiasis in India. Br Med J 1903;1:1252-4
6. Donovan C. On the possibility of the occurrence of trypano-somiasis in India. Br Med J 1903;2:79
7. Lumsden WHR. Leishmaniasis and trypanosomiasis: The causative organisms compared and contrasted. In: Trypanosomiasis and leishmaniasis with special reference to Chagas disease. Ciba Found Symp 1974;20:3-27
8. Chulay JD. Leishmaniasis. In: Strickland GT, ed. Hunter’s tropical medicine. 6th ed. Philadelphia: W. B. Saunders, 1984:547-93
9. Marsden PD. Leishmaniasis. N Engl J Med 1979;300:350-2
10. Marsden PD. Selective primary health care: Strategies for control of disease in the developing world. XIV. Leishmaniasis. Rev Infect Dis 1984;6:736-44
11. Kreutzer RD, Semko ME, Hendricks LD, Wright N. Iden-tification of Leishmania spp. by multiple isozyme analysis. Am J Trop Med Hyg 1983;32:703-15
12. Wirth DF, Pratt DM. Rapid identification of Leishmania species by specific hybridization of kinetoplast DNA in cutaneous lesions. Proc Natl Acad Sei USA 1982;79: 6999-7003
13. Wirth DF, Rogers WO, Barker R Jr, Dourado H, Suesebang L, Albuquerque B. Leishmaniasis and malaria: New tools for epidemiologic analysis. Science 1986;234:975-9
14. Beverley SM, Ismach RB, Pratt DM. Evolution of the ge-nus Leishmania as revealed by comparisons of nuclear DNA restriction fragment patterns. Proc Natl Acad Sei USA 1987;84:484-8
15. Chang K-P, Fong D, Bray RS. Biology of Leishmania and leishmaniasis. In: Chang K-P, Bray RS, eds. Human parasitic diseases. Vol 1. Amsterdam: Elsevier, 1985:1-30
16. Chance ML. The biochemical and immunological taxonomy of Leishmania. In: Chang K-P, Bray RS, eds. Human parasitic diseases. Vol 1. Amsterdam: Elsevier, 1985:93-110
17. Jackson PR, Wohlhieter JA, Jackson JE, Sayles P, Diggs CL, Hockmeyer WT. Restriction endonuclease analysis of Leishmania kinetoplast DNA characterizes parasites responsible for visceral and cutaneous disease. Am J Trop Med Hyg 1984;33:808-19
18. Alexander J, Vickerman K. Fusion of host cell secondary lysosomes with the parasitophorous vacuoles of Leishmania mexicana-infeeted macrophages. J Protozool 1975; 22:502-8
19. Chang K-P, Dwyer DM. Multiplication of human parasite[Leishmania donovani) in phagolysosomes of hamster macrophages in vitro. Science 1976;193:678-80
20. Berman JD, Fioretti TB, Dwyer DM. In vivo and in vitro localization of Leishmania within macrophage phagolysosomes: Use of colloidal gold as a lysosomal label. J Protozool 1981;28:239-42
21. Pan AA. Leishmania mexicana: Serial cultivation of intra-cellular stages in a cell-free medium. Exp Parasitol 1984; 58:72-80
22. Ashford RW, Smith DH. Leishmaniasis in Sudan, Ethiopia and Kenya. In: Chang K-P, Bray RS, eds. Human parasitic diseases. Vol 1. Amsterdam: Elsevier, 1985:377-91
23. Safjanova VM. Leishmaniasis in the USSR. In: Chang K-P, Bray RS, eds. Human parasitic diseases. Vol 1. Amsterdam: Elsevier, 1985:427-42
24. Senekji HA, Bcattie CP. Artificial infection and immuni-zation of man with cultures of Leishmania tropica. Trans R Soc Trop Med Hyg 1941;34:415-9
25. Killick-Kendrick R, Bryceson ADM, Peters W, Evans DA, Leaney AJ, Rioux JA. Zoonotic cutaneous leishmaniasis in Saudi Arabia: Lesions healing naturally in man followed by a second infection with the same zymodeme of Leishmania major. Trans R Soc Trop Med Hyg 1985; 79:363-5
26. Belazzoug S, Neal RA. Failure of meglumine antimoniate to cure cutaneous lesions due to Leishmania major in Algeria [letter]. Trans R Soc Trop Med Hyg 1986;80:670-1
27. Convit J, Castellanos PL, Rondon A, Panardi ME, Ulrich M, Castes M, Bloom B, Garcia L. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1987;1:401-4
28. Low-A-Chee RM, Rose P, Ridley DS. An outbreak of cuta-neous leishmaniasis in Guyana: Epidemiology, clinical and laboratory aspects. Ann Trop Med Parasitol 1983;77:255-60
29. Ballou WR, McClain JB, Gordon DM, Shanks GD, Andu-jar J, Berman JD, Chulay JD. Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet 1987;2:13-6
30. Llanos Cueutas EA, Cuba CC, Barreto AC, Marsden PD.Clinical characteristics of human Leishmania brazilien-sis braziliensis infections [letter]. Trans R Soc Trop Med Hyg 1984;78:845-6
31. Marsden PD, Llanos Cueutas EA, Lago EL, Cuba CC, Bar-reto AC, Costa JM, Jones TC. Human mucocutaneous leishmaniasis in Tres Bracos, Bahia-Brazil. An area of Leishmania braziliensis braziliensis transmission. III. Mucosal disease presentation and initial evolution. Revista da Sociedade Brasileira de Medicina Tropical 1984; 17:179-86
32. Walton BC, Chinel LV, Equia Y Eguia O. Onset of espundia after many years of occult infection with Leishmania braziliensis. Am J Trop Med Hyg 1973;22:696-8
33. Marsden PD. Mucosal leishmaniasis. Trans R Soc Trop Med Hyg 1986;80:859-76
34. Lainson R, Strangways-Dixon J. Leishmania mexicana: The epidemiology of dermal leishmaniasis in British Honduras. Trans R Soc Trop Med Hyg 1963;57:242-65
35. Llanos-Cueutas EA, Marsden PD, Lago EL, Barreto AC, Cuba CC, Johnson WD. Human mucocutaneous leishmaniasis in Tres Bracos, Bahia-Brazil. An area of Leishmania braziliensis braziliensis transmission. II. Cutaneous disease. Presentation and evaluation. Revista da Sociedade Brasileira de Medicina Tropical 1984;17:169-77
36. Marsden PD, Tada MS, Barreto AC, Cuba CC. Spontane-ous healing of Leishmania braziliensis braziliensis skin ulcers [letter]. Trans R Soc Trop Med Hyg 1984;78:561-2
37. Marsden PD, Cuba CC, Barreto AC, Sampaio RN, Rocha RAA. Nifurtimox in the treatment of South American leishmaniasis. Trans R Soc Trop Med Hyg 1979;73:391-4
38. Cole ACE. Kala-azar in East Africa. Trans R Soc Trop Med Hyg 1944;37:409-35
39. Most H, Lavietes PH. Kala azar in American military person-nel: Report of 30 cases. Medicine (Baltimore) 1947;26:221-84
40. Chulay JD, Bhatt SM, Muigai R, Ho M, Gachihi G, Were JBO, Chunge C, Bryceson ADM. A comparison of three dosage regimens of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya. J Infect Dis 1983; 148:148-55
41. Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, Teixeira R, Johnson WD Jr. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986;154:1003-11
42. Hashemi-Nasab A, Zadeh-Shirazi H. Visceral leishmania-sis (kala-azar) in Fars Province, Iran: Study of 130 cases. J Trop Med Hyg 1980;83:119-22
43. Naik SR, Rao PN, Datta DV, Mehta SK, Mahajan RC, Mehta S, Chhuttani PN. Kala-azar in north-western India: A study of 24 patients. Trans R Soc Trop Med Hyg 1979;73:61-5
44. Manson-Bahr PEC. East African kala-azar with special ref-erence to the pathology, prophylaxis and treatment. Trans R Soc Trop Med Hyg 1959;53:123-37
45. Report of the informal meeting on the chemotherapy of vis-ceral leishmaniasis. Document no. TDR CHEMLEISH/VL/82.3. Geneva: World Health Organization, 1982
46. Rees PH, Kager PA, Wellde BT, Hockmeyer WT. The re-sponse of Kenyan kala-azar to treatment with sodium stibogluconate. Am J Trop Med Hyg 1984;33:357-61
47. Hicsönmez G, Özsoylu S. Kala-azar in childhood. A survey of clinical and laboratory findings and prognosis in 44 childhood cases. Clin Pediatr 1972;11:465-7
48. Pampiglione S, Manson-Bahr PEC, Giungi F, Giunti G, Parenti A, Canestri-Trotti G. Studies on Mediterranean leishmaniasis. II. Asymptomatic cases of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1974;68:447-53
49. Zilberstein D, Dwyer DM. Protonmotive force-driven active transport of D-glucose and L-proline in the protozoan parasite Leishmania donovani. Proc Natl Acad Sei USA 1985; 82:1716-20
50. Berman JD, Gallalee JV, Best JM, Hill T. Uptake, distribu-tion and oxidation of fatty acids by Leishmania mexicana amastigotes. J Parasitol 1987;73:555-60
51. Hart DT, Vickerman K, Coombs GH. Transformation in vitro of Leishmania mexicana amastigotes to promasti-gotes: Nutritional requirements and the effect of drugs. Parasitology 1981;83:529-41
52. Hart DT, Coombs GH. Leishmania mexicana: Energy meta-bolism of amastigotes and promastigotes. Exp Parasitol 1982;54:397-409
53. Berman JD, Gallalee JV, Best JM. Sodium stibogluconate(Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid ß-oxidation in Leishmania mexicana amastigotes. Biochem Pharmacol 1987;36: 197-201
54. Martin E, Simon MW, Schaefer FW III, Mukkada AJ. En-zymes of carbohydrate metabolism in four human species of Leishmania: A comparative study. J Protozool 1976; 23:600-7
55. Berens RL, Deutsch-King LC, Marr JJ. Leishmania donovani and Leishmania braziliensis: Hexokinase, glucose 6-phos-phate dehydrogenase and pentose phosphate shunt activity. Exp Parasitol 1980;49:1-8
56. Marr JJ. Carbohydrate metabolism in Leishmania. In: Levandowsky M, Hunter SH, eds. Biochemistry and physiology of protozoa. 2nd ed. Vol 3. New York: Academic Press, 1980:313-40
57. Coombs GH, Craft JA, Hart DT. A comparative study of Leishmania mexicana amastigotes and promastigotes. Enzyme activities and subcellular locations. Mol Biochem Parasitol 1982;5:199-211
58. Mottram JC, Coombs GH. Leishmania mexicana: Enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals. Exp Parasitol 1985;59:151-60
59. Meade JC, Glaser TA, Bonventre PF, Mukkada AJ. Enzymes of carbohydrate metabolism in Leishmania donovani amastigotes. J Protozool 1984;31:156-61
60. Mukkada AJ. Tricarboxylic acid and glyoxylate cycles in the leishmaniae. Acta Trop (Basel) 1977;34:167-75
61. Simon MW, Martin E, Mukkada AJ. Evidence for a functional glyoxylate cycle in the leishmaniae. J Bacteriol 1978;135:895-9
62. Hart DT, Opperdoes FR. The occurrence of glycosomes (microbodies) in the promastigote stage of four major Leishmania species. Mol Biochem Parasitol 1984;13:159-72
63. Coombs GH, Tetley L, Moss VA, Vickerman K. Three di-mensional structure of the Leishmania amastigote as revealed by computer-aided reconstruction from serial sections. Parasitology 1986;92:13-23
64. Hammond DJ, Gutteridge WE, Opperdoes FR. A novel location for two enzymes of de novo pyrimidine biosynthesis in trypanosomes and Leishmania. FEBS Lett 1981;128:27-9
65. Berman JD, Waddell D, Hanson BD. Biochemical mecha-nisms of the antileishmanial activity of sodium stibogluconate. Antimicrob Agents Chemother 1985;27:916-20
66. Berman JD, Grogl M. Biochemical mechanisms of Pento-stam. In: Hart DT, ed. Leishmaniasis (NATO ASI Series). New York: Plenum, 1988 (in press)
67. Marr JJ, Berens RL. Pyrazolopyrimidine metabolism in the pathogenic Trypanosomatidae. Mol Biochem Parasitol 1983;7:339-56
68. Marr J J, Berens RL. Purine and pyrimidine metabolism in Leishmania. In: Chang K-P, Bray RS, eds. Human parasitic diseases. Vol 1. Amsterdam: Elsevier, 1985:65-78
69. Marr JJ, Berens RL, Nelson DJ. Purine metabolism in Leish-mania donovani and Leishmania braziliensis. Biochim Biophys Acta 1978;544:360-71
70. LaFon SW, Nelson DJ. Purine and pyrimidine salvage path-ways in Leishmania donovani. Biochem Pharmacol 1982; 31:231-8
71. Looker DL, Berens RL, Marr JJ. Purine metabolism in Leish-mania donovani amastigotes and promastigotes. Mol Biochem Parasitol 1983;9:15-28
72. Hassan HF, Coombs GH. Leishmania mexicana. Purine-metabolizing enzymes of amastigotes and promastigotes. Exp Parasitol 1985;59:139-50
73. Berens RL, Marr JJ, Nelson DJ, LaFon SW. Antileishmanial effect of allopurinol and allopurinol ribonucleoside on intracellular forms of Leishmania donovani. Biochem Pharmacol 1980;29:2397-8
74. Berman JD, Rainey P, Santi DV. Metabolism of formycin B by Leishmania amastigotes in vitro. Comparative metabolism in infected and uninfected human macrophages. J Exp Med 1983;158:252-7
75. Spector T, Jones TE, Elion GB. Specificity of adenylosuc-cinate synthetase and adenylosuccinate lyase from Leishmania donovani. Selective amination of an antiprotozoal agent. J Biol Chem 1979;254:8422-6
76. Nelson DJ, LaFon SW, Tuttle JV, Miller WH, Miller RL, Krenitsky TA, Elion GB, Berens RL, Marr J J. Allopurinol ribonucleoside as an antileishmanial agent. Biological effects, metabolism, and enzymatic phosphorylation. J Biol Chem 1979;254:11544-9
77. Carson DA, Chang K-P. Phosphorylation and anti-leishmanial activity of formycin B. Biochem Biophys Res Commun 1981;100:1377-83
78. Nelson DJ, LaFon SW, Jones TE, Spector T, Berens RL, Marr JJ. The metabolism of formycin B in Leishmania donovani. Biochem Biophys Res Commun 1982;108:349-54
79. Rainey P, Santi DV. Metabolism and mechanism of action of formycin B in Leishmania. Proc Natl Acad Sei USA 1983;80:288-92
80. Wataya Y, Hiraoka O. 3’-Deoxyinosine as an anti-leishmanial agent: The metabolism and cytotoxic effects of 3’-deoxy-inosine in Leishmania tropica promastigotes. Biochem Biophys Res Commun 1984;123:677-83
81. LaFon SW, Nelson DJ, Berens RL, Marr JJ. Inosine analogs: Their metabolism in mouse L cells and in Leishmania donovani. J Biol Chem 1985;260:9660-5
82. Hiraoka O, Satake H, Iguchi S, Matsuda A, Ueda T, Wataya Y. Carbocyclic inosine as a potent anti-leishmanial agent: The metabolism and selective cytotoxic effects of carbocyclic inosine in promastigotes of Leishmania tropica and Leishmania donovani. Biochem Biophys Res Commun 1986;134:1114-21
83. Spector T, Jones TE. Guanosine 5’-monophosphate reductase from Leishmania donovani. A possible chemotherapeutic target. Biochem Pharmacol 1982;31:3891-7
84. Looker DL, Marr J J, Berens RL. Mechanisms of action of pyrazolopyrimidines in Leishmania donovani. J Biol Chem 1986;261:9412-5
85. Nelson DJ, LaFon SW, Elion GB, Marr JJ, Berens RL. Comparative metabolism of a new antileishmanial agent, allopurinol riboside, in the parasite and the host cell. In: Rapado A, Watts RWE, DeBruyn CHMM, eds. Purine metabolism in man -III. Vol. 122B. New York: Plenum, 1980:7-12
86. Berman JD. Inhibition of leishmanial protein kinase by antileishmanial drugs. Am J Trop Med Hyg 1988 (in press)
87. Nolan LL, Berman JD, Giri L. The effect of formycin B on mRNA translation and uptake of purine precursors in Leishmania mexicana. Biochem Int 1984;9:207-18
88. Rainey P, Santi DV. Formycin B resistance in Leishmania.Biochem Pharmacol 1984;33:13747
89. Robinson N, Kaur K, Emmett K, Iovannisci DM, Ullman B. Biochemical genetic analysis of formycin B action in Leishmania donovani. J Biol Chem 1984;259:7637-43
90. Holz GG. Lipids of Leishmania. In: Chang K-P, Bray RS, eds. Human parasitic diseases. Vol 1. Amsterdam: Elsevier, 1985:79-92
91. Beach DH, Holz GG Jr, Anekwe GE. Lipids of Leishmania promastigotes. J Parasitol 1979;65:203-16
92. Beach DH, Holz GG Jr, Semprevivo LH, Honigberg BM.Temperature-dependent fatty acyl group changes in phospholipids of 37C-adapted Leishmania donovani promastigotes. J Parasitol 1982;68:1004-9
93. Wassef MK, Fioretti TB, Dwyer DM. Lipid analysis of isolated surface membranes of Leishmania donovani promastigotes. Lipids 1985;20:108-15
94. Herrmann HO, Hintze U, Gercken G. Ether lipid synthesis from enantiomeric medium-chain and long-chain O-alkyl-sn-glycerols in Leishmania donovani promastigotes. Mol Biochem Parasitol 1981;3:319-25
95. Herrmann HO, Gercken G. Metabolism of l-0-[l’-14C]-octadecyl-SN-glycerol in Leishmania donovani promastigotes. Ether lipid synthesis and degradation of the ether bond. Mol Biochem Parasitol 1982;5:65-76
96. Fish WR, Holz GG Jr, Beach DH, Owen E, Anekwe GE.The cyclopropane fatty acid of trypanosomatids. Mol Biochem Parasitol 1981;3:103-15
97. Semprevivo LH, MacLeod ME. Characterization of the exometabolite of Leishmania donovani as a novel glycopep-tidophosphosphingolipid. Biochem Biophys Res Commun 1981;103:1179-85
98. Biosynthesis of cholesterol and related substances. In: Mead JF, Alfun-Slater RB, Howten DR, Popjak G, eds. Lipids. Chemistry, biochemistry, and nutrition. New York: Plenum, 1986:295-367.
99. Goad LJ, Holz GG Jr, Beach DH. Sterols of Leishmania species. Implications for biosynthesis. Mol Biochem Parasitol 1984;10:161-70
100. Berman JD, Holz GG Jr, Beach DH. Effects of ketoconazole on growth and sterol biosynthesis of Leishmania mexicana promastigotes in culture. Mol Biochem Parasitol 1984;12:1-13
101. Goad LJ, Holz GG Jr, Beach DH. Sterols of ketoconazoleinhibited Leishmania mexicana mexicana promastigotes. Mol Biochem Parasitol 1985;15:257-79
102. Berman JD, Goad LJ, Beach DH, Holz GG Jr. Effects of ketoconazole on sterol biosynthesis by Leishmania mexicana mexicana amastigotes in murine macrophage tumor cells. Mol Biochem Parasitol 1986;20:85-92
103. Kobayashi GS, Medoff G. Antifungal agents: Recent developments. Annu Rev Microbiol 1977;31:291-308
104. Cohen BE, Ramos H, Gamargo M, Urbina J. The water and ionic permeability induced by polyene antibiotics across plasma membrane vesicles from Leishmania sp. Biochim Biophys Acta 1986;860:57-65
105. Saha AK, Mukherjee T, Bhaduri A. Mechanism of action of amphotericin B on Leishmania donovani promastigotes. Mol Biochem Parasitol 1986;19:195-200
106. Van den Bossche H, Willemsens G, Cools W, Marichal P, Lauwers W. Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. Biochem Soc Trans 1983;11:665-7
107. Bloch K. Sterol structure and membrane function. CRC Crit Rev Biochem 1983;14:47-92
108. Goad L J, Holz GG Jr, Beach DH. Effect of the allylamine antifungal drug SF 86-327 on the growth and sterol synthesis of Leishmania mexicana mexicana promastigotes. Biochem Pharmacol 1985;34:3785-8
109. McCann PP, Bacchi CJ, Hanson WL, Cain GD, Nathan HC, Hutner SH, Sjoerdsma A. Effect on parasitic protozoa of a-difluoromethylornithine -an inhibitor of ornithine decarboxylase In: Caldarera CM, Zappia V, Bach-rach U, eds. Advances in polyamine research. Vol. 3. New York: Raven Press, 1981:97-110
110. Bachrach U, Abu-Elheiga L, Talmi M, Schnur LF, El-On J, Greenblatt CL. Polyamines and the growth of leishmanial parasites. Med Biol 1981;59:441-7
111. Bachrach U, Brem S, Wertman SB, Schnur LF, Greenblatt CL. Leishmania spp: Effect of inhibitors on growth and on polyamine and macromolecular synthesis. Exp Parasitol 1979;48:464-70
112. Bachrach U, Abu-Elheiga L, Schnur LF. Leishmania tropica major: Effect of paromomycin and pentamidine on polyamine levels in the skin of normal and infected mice. Exp Parasitol 1983;55:280-8
113. Hentzer B, Kobayasi T. The ultrastructural changes of Leishmania tropica after treatment with pentamidine. Ann Trop Med Parasitol 1977;71:157-66
114. Langreth SG, Berman JD, Riordan GP, Lee LS. Fine-structural alterations in Leishmania tropica within human macrophages exposed to antileishmanial drugs in vitro. J Protozool 1983;30:555-61
115. Croft SL, Brazil RP. Effect of pentamidine isothionate on the ultrastructure and morphology of Leishmania mexicana amazonensis in vitro. Ann Trop Med Parasitol 1982; 76:37-43
116. Rollo IM. Miscellaneous drugs used in the treatment of protozoal infections. In: Goodman LS, Gilman A, eds. The pharmacological basis of therapeutics. 3rd ed. New York: Macmillan, 1965:1135-43
117. Kirk R, Sati MH. Observations on the use of sodium antimony gluconate (sodium stibogluconate) in the treatment of kala-azar. Ann Trop Med Parasitol 1947;41:14-21
118. Tuckman E. Treatment of Chinese kala-azar with sodium antimony gluconate. J Trop Med Hyg 1949;52:199-204
119. Yan-Jia L. A review of kala-azar in China from 1949 to 1959.Trans R Soc Trop Med Hyg 1982;76:531-7
120. Wijers DJB. A ten years’ study of kala-azar in Tharaka (Meru District, Kenya). II. Relapses. East Afr Med J 1971;48:551-8
121. Informational material for physicians. Pentostam (sodium stibogluconate). Protocol no. 53. Atlanta: Center for Disease Control
122. Anabwani GM, Dimiti G, Ngira JA, Bryceson ADM. Comparison of two dosage schedules of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya. Lancet 1983;1:210-2
123. The leishmaniases. Report of a WHO Expert Committee.WHO Tech Rep Ser 1984;701:99-109
124. Thakur CP, Kumar M, Singh SK, Sharma D, Prasad US, Singh RSP, Dhawan PS, Achari V. Comparison of regimens of treatment with sodium stibogluconate in kala-azar. Br Med J 1984;288:895-7
125. Marsden PD. Pentavalent antimonials: Old drugs for new diseases. Revista da Sociedade Brasileira de Medicina Tropical 1985;18:187-98
126. Steck EA. The chemotherapy of protozoan disease. Washington, DC: Division of Medicinal Chemistry, Walter Reed Army Institute of Research, U.S. Government Printing Office, 1972;7.1-7:141
127. Shortt HE. Recent research on kala-azar in India. Trans R Soc Trop Med Hyg 1945;39:13-31
128. Chulay JD, Spencer HC, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 1985;34:702-9
129. Mainzer F, Krause M. Changes of the electrocardiogram appearing during antimony treatment. Trans R Soc Trop Med Hyg 1940;33:405-18
130. Schroeder EF, Rose FA, Most H. Effect of antimony on the electrocardiogram. Am J Med Sci 1946;212:697-706
131. Honey M. The effects of sodium antimony tartrate on the myocardium. Br Heart J 1960;22:601-16
132. Davis A. Comparative trials of antimonial drugs in urinary schistosomiasis. Bull WHO 1968;38:197-227
133. Chulay JD, Fleckenstein L, Smith DH. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimonate. Trans R Soc Trop Med Hyg 1988; in press.
134. Rees PH, Keating MI, Kager PA, Hockmeyer WT. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet 1980;2:226-9
135. Berman JD. Leishmaniasis. In: Rakel RE, ed. Conn’s current therapy. Philadelphia: W. B. Saunders, 1987:63-5
136. Sampaio RNR, Sampaio JHD, Marsden PD. Pentavalent antimonial treatment in mucosal leishmaniasis [letter]. Lancet 1985;1:1097
137. Bryceson ADM, Chulay JD, Mugambi M, Were JB, Gachihi G, Chunge CN, Muigai R, Bhatt SM, Ho M, Spencer HC, Meme J, Anabwani G. Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high-dosage sodium stibogluconate or prolonged treatment with pentamidine. Trans R Soc Trop Med Hyg 1985;79:705-14
138. Dietze R, Araujo RC, Lima MLR, Vexenat JA, Marsden PD, Barreto AC. Ensaio terapéutico con. Glucantime em saquis (callithrox jacchus) infectados com una cepa de Leishmania donovani aparentemente resistente ao trata-mouto. Revista da Sociedade Brasileira de Medicina Tropical 1985;18:39-42
139. Berman JD, Chulay JD, Hendricks LD, Oster CN. Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. Am J Trop Med Hyg 1982;31:459-65
140. Berman JD, Lee LS. Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. J Parasitol 1984;70:220-5
141. Guerra MFV, Marsden PD, Cuba CC, Barreto AC. Further trials of nifurtimox in mucocutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1981;75:335-7
142. Berman JD, Lee LS. Activity of oral drugs against Leishmania tropica in human macrophages in vitro. Am J Trop Med Hyg 1983;32:947-51
143. Kurban AK, Malak JA, Farah FS, Siage J, Jallad M. Treatment of cutaneous leishmaniasis (oriental sore) with a new repository antimalarial. J Trop Med Hyg 1969;72:86-8
144. Ardehali M. Treatment of cutaneous leishmaniasis with cycloguanil pamoate. In J Dermatol 1974;13:26-8
145. Walton BC, Person DA, Ellman MH, Bernstein R. Treatment of American cutaneous leishmaniasis with cyclo-guanil pamoate. Am J Trop Med Hyg 1968;17:814-8
146. Johnson CM. Cycloguanil pamoate in the treatment of cutaneous leishmaniasis: Initial trials in Panama. Am J Trop Med Hyg 1968;17:819-22
147. Salem HH, Hayaty ZG, Awaness AM, Al-Allaf G. The treatment of cutaneous leishmaniasis with oral dehydroeme-tine. Trans R Soc Trop Med Hyg 1967;61:776-80
148. Peters W, Lainson R, Shaw J J, Robinson BL, Leäo AF. Potentiating action of rifampicin and isoniazid against Leishmania mexicana amazonensis. Lancet 1981;1:1122-3
149. Saha SK. Dermal leishmaniasis after kala-azar infection:successful treatment with rifampin. Cutis 1985;36:81-2
150. Van Der Meulen J, Mock B, Fekete E, Serojini PA. Limitedtherapeutic action of rifampicin/isoniazid against Leishmania aethiopica [letter]. Lancet 1981;2:197-8
151. Pedersen JK, Sawicki S. Metronidazole therapy for cutaneous leishmaniasis. Arch Dermatol 1975;111:1343-4
152. Walton BC, Paulson JE, Arjona MA, Peterson CA. American cutaneous leishmaniasis: Inefficiency of metronidazole in treatment. JAMA 1974;228:1256-8
153. Kandil E. Treatment of cutaneous leishmaniasis with trimethoprim-sulfamethoxazole combination. Dermatológica 1973;146:303-9
154. Dogra J, Lai BB, Misra SN. Dapsone in the treatment of cutaneous leishmaniasis. Int J Dermatol 1986;25:398-400
155. Barsky S, Storino W, Salgea K, Knapp DP. Cutaneous leish maniasis: Surgical management of a case with unusual clinical and histological features. Arch Dermatol 1978; 114:1354-5
156. Bassiouny A, El Meshad M, Talaat M, Kutty K, Metawaa B. Cryosurgery in cutaneous leishmaniasis. Br J Dermatol 1982;107:467-74
157. Faber WR. Cryosurgery for cutaneous leishmaniasis. J Dermatol Surg Oncol 1983;9:354-6
158. Berman JD, Neva FA. Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro. Am J Trop Med Hyg 1981; 30:318-21
159. Sacks DL, Barral A, Neva FA. Thermosensitivity patterns of Old vs. New World cutaneous strains of Leishmania growing within mouse peritoneal macrophages in vitro. Am J Trop Med Hyg 1983;32:300-4
160. Neva FA, Petersen EA, Corsey R, Bogaert H, Martinez D.Observations on local heat treatment for cutaneous leishmaniasis. Am J Trop Med Hyg 1984;33:800-4
161. Barrios LA, Costa JML, Netto EM, Vexenat COR, Cuba CC, Marsden PD. Intralesional Glucantime in Leishmania braziliensis braziliensis infections petter]. Trans R Soc Trop Med Hyg 1986;80:173-4
162. Kellum RE. Treatment of cutaneous leishmaniasis with an intralesional antimonial drug (Pentostam). J Am Acad Dermatol 1986;15:620-2
163. Brenner S. Topical treatment with imidazole for cutaneous leishmaniasis, tsr J Med Sei 1985;21:163-4
164. El-On J, Livshin R, Even-Paz Z, Hamburger D, Weinrauch L. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1986;87:284-8
165. Rees PH, Kager PA, Ogada T, Eeftinck Schattenkerk JK.The treatment of kala azar: A review with comments drawn from experience in Kenya. Trop Geogr Med 1985;37:37-46
166. Sands M, Kron MA, Brown RB. Pentamidine: A review. Rev Infect Dis 1985;7:625-34
167. Thakur CP. Epidemiological, clinical and therapeutic features of Bihar kala-azar. Trans R Soc Trop Med Hyg 1984;78:391-8
168. Jha TK. Evaluation of diamidine compounds (pentamidine isethionate) in the treatment of resistant cases of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983;77:167-70
169. Prata A. Treatment of kala-azar with amphotericin B. Trans R Soc Trop Med Hyg 1963;57:266-8
170. Sampaio SAP, Godoy JT, Paiva L, Dillon NL, Lacaz CS. The treatment of American (mucocutaneous) leishmaniasis with amphotericin B. Arch Dermatol 1960;82:627-35
171. Sampaio SAP, Castro RM, Dillon NL, Martins JEC. Treat ment of mucocutaneous (American) leishmaniasis with amphotericin B: Report of 70 cases. Int J Dermatol 1971; 10:179-81
172. Singer C, Armstrong D, Jones TC, Spiro RH. Imported mucocutaneous leishmaniasis in New York City. Report of a patient treated with amphotericin B. Am J Med 1975;59:444-7
173. Jha TK. Evaluation of allopurinol in the treatment of kala azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983;77:204-7
174. Hande K, Reed E, Chabner R. Allopurinol kinetics. Clin Pharmacol Ther 1978;23:598-605
175. Allopurinol ribonucleoside: Information for clinical investi gators. Research Triangle Park, NC: Burroughs Wellcome, 1984:3-12
176. Kager PA, Rees PH, Wellde BT, Hockmeyer WT, Lyerly WH.Allopurinol in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1981;75:556-9
177. Chunge CN, Gachihi G, Muigai R, Wasuna K, Rashid JR, Chulay JD, Anabwani G, Oster CN, Bryceson ADM. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg 1985;79:715-8
178. Kager PA, Rees PH, Manguyu FM, Bhatt KM, Wellde BT, Hockmeyer WT, Lyerly WH Jr. Clinical, haematologi-cal and parasitological response to treatment of visceral leishmaniasis in Kenya. A study of 64 patients. Trop Ge-ogr Med 1984;36:21-35
179. Berman JD. Experimental chemotherapy of leishmaniasis-acritical review. In: Chang K-P, Bray RS, eds. Human parasitic diseases. Vol 1. Amsterdam: Elsevier, 1985:111-38
180. Urcuyo FG, Zaias N. Oral ketoconazole in the treatment of leishmaniasis. Int J Dermatol 1982;21:414-6
181. Jolliffe DS. Cutaneous leishmaniasis from Belize-treatment with ketoconazole. Clin Exp Dermatol 1986;11:62-8
182. Dedet JP, Jamet P, Esterre P, Ghipponi PM, Genin C, Lalande G. Failure to cure Leishmania braziliensis guyanensis cutaneous leishmaniasis with oral ketoconazole [letter]. Trans R Soc Trop Med Hyg 1986;80:176
183. Weinrauch L, Livshin R, El-On J. Cutaneous leishmaniasis: Treatment with ketoconazole. Cutis 1983;32:288-9, 294
184. Belazzoug S, Ammar-Khodja A, Belkaid M, Tabet-Derraz O. La leishmaniose cutanee du nord de L’Algerie. Bull Soc Pathol Exot Filiales 1985;78:615-22
185. Viallet J, Maclean JD, Robson H. Response to ketoconazole in two cases of longstanding cutaneous leishmaniasis. Am J Trop Med Hyg 1986;35:491-5
186. Borelli D. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Rev Infect Dis 1987; 9(Suppl l): S57-63
187. Berman JD, Hanson WL, Chapman WL, Alving CR, LopezBerestein G. Antileishmanial activity of liposome-encap-sulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother 1986;30:847-51